|会社名||Mesabi Trust （MESABI TRUST）|
|概要||メサビ・トラスト（Mesabi Trust）（同信託）はロイヤルティー・トラストである。同信託はメサビ鉄山東部のミネソタ州バビットに位置する鉄鉱山（Peter Mitchell Mine）から収益を挙げる。同信託は、信託財産を保護・保全するほか、費用と負債の支払い後(提供)で信託の承認保有者のために、収入・収益を収集・分配する。信託契約により、同信託が行うロイヤルティーと費用の支払い以外の事業活動は禁止される。同信託鉱物権益の借主・オペレーターはCliffs Natural Resources Inc (Cliffs)の子会社であるNorthshore Mining Corporation (NMC)。Cliffs Natural Resources Incは鉄鉱製品の生産者である。同信託はMesabi Iron Companyが所有していた全部の権利を保有する。 メサビ・トラストは、米国の信託会社。ミネソタ州セントルイス郡に広がる土地に位置するメサビ鉄山において二つのプロジェクト「Peters Lease」と「Cloquet Lease」の投資を手掛ける。Peters Lease Landsの所有者として20％の利子を取得するほか、隣接する非鉱物生産地の所有者として100％のリ―ス手数料を所有。 Mesabi Trust engages in the collection and distribution of royalties and payment of expenses and liabilities. It holds interest in Peter Mitchell iron mine located near Babbitt and in Silver Bay, Minnesota. The company was founded on July 18, 1961 and is headquartered in New York, NY.|
|本社所在地||c/o Deutsche Bank Trust Company Americas Trust_Agency Services 60 Wall Street 16th Floor New York NY 10005 USA|
|決算概要||BRIEF: For the nine months ended 31 October 2018 Mesabi Trust revenues increased 33% to $39.8M. Net income increased 33% to $38.8M. Revenues reflect Interest increase from $40K to $147K. Dividend per share increased from $1.98 to $2.55. Basic Earnings per Share excluding Extraordinary Items increased from $2.22 to $2.96.|
Why Brinker International Shares Look Tasty 2020/10/16 23:30:00 Barron's
Margin improvements and cost cuts could produce earnings above $5 a share when the pandemic ends. Also, Wall Street opinions on the stocks of UnitedHealth Group, PNC Financial Services, Albertsons, and Mesoblast
ROSEN, GLOBAL INVESTOR COUNSEL, Reminds Mesoblast Limited Investors of Important December 7 Deadline in Securities Class Action– MESO 2020/10/16 21:01:00 Business Wire
NEW YORK--(BUSINESS WIRE)--Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Mesoblast Limited (NASDAQ: MESO) between April 16, 2019 and October 1, 2020, inclusive (the “Class Period”), of the important December 7, 2020 lead plaintiff deadline in the securities class action. The lawsuit seeks to recover damages for Mesoblast investors under the federal securities laws. To join the Mesoblast class action, go to http://www.rosenlegal.com/cases-register-192
Stem Cell Market 2020 – Impact of COVID-19, Future Growth Analysis and Challenges | Anterogen Co., Ltd, Mesoblast Ltd, Osiris Therapeutics, Inc, AlloSource 2020/10/16 10:59:28 OpenPR
The Business Research Company offers "Stem Cell Global Market Report 2020-30: Covid 19 Growth And Change" in its research report store. It is the most comprehensive report available on this market and will help gain a truly global perspective as
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mesoblast Limited (MESO) 2020/10/15 15:30:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $MESO #CLASSACTION--Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mesoblast Limited (MESO)
Notice of Lead Plaintiff Deadline for Shareholders in the Mesoblast Limited Class Action Lawsuit 2020/10/14 13:00:00 Business Wire
SAN DIEGO--(BUSINESS WIRE)--The suit alleges defendants issued false statements concerning Mesoblast business and prospects, resulting in its stock trading at inflated prices.
Great start to the week for Aussie stocks: ASX closed 2.6% higher 2020/10/05 06:21:39 Finance News Network
05 Oct 2020 - It has been a positive day of trade for the ASX the local bourse managed to close 2.6% higher. Shares in Mesoblast (ASX:MSB) did well today, rising over 11%. Gold miners were hit today though with Evolution Mining (ASX:EVN) and Newcrest (ASX:NCM) both falling. McMillan Shakespeare (ASX:MMS) has settled a class action today.
The Week Ahead In Biotech: Avenue's FDA Decision, Alkermes Adcom Meeting, Aziyo Biologics IPO 2020/10/04 14:00:07 Benzinga
Biotech stocks made a steady recovery over the week ended Oct. 2, although Friday's weakness trimmed some of the gains of the week. Companies working on anti-COVID-19 antibody treatments were in the news during the week. Sorrento Therapeutics Inc. (NASDAQ: SRNE ) announced a second more potent preclinical antibody candidate, while Regeneron Pharmaceuticals Inc. (NASDAQ: REGN ) released preliminary readout for its antibody cocktail in treating non-hospitalized COVID-19 patients. On the FDA approval front, Eton Pharmaceuticals Inc. (NASDAQ: ETON ) received the nod for its Alkindi Sprinkle as a hormone replacement therapy for treating adrenocortical insufficiency in children under 17 years of age. Mesoblast (NASDAQ: MESO ), however, was in for a disappointment. Its stem cell therapy for acute graft versus host disease was turned down by the regulatory agency. Zosano Pharma Corp. (NASDAQ: ZSAN ) shares wilted on a deficiency review letter for the NDA for its migraine patch. Selecta Biosciences Inc.
Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Mesoblast Limited (MESO) on Behalf of Investors 2020/10/03 00:28:00 Business Wire
LOS ANGELES--(BUSINESS WIRE)---- $MESO #CLASSACTION--Glancy Prongay & Murray LLP, a Leading Securities Fraud Law Firm, Announces Investigation of Mesoblast Limited (MESO) on Behalf of Investors
Mesoblast (ASX:MSB) hits approval hurdle: Aus shares 0.9% lower at noon 2020/10/02 04:16:41 Finance News Network
02 Oct 2020 - The Australian share market opened lower and continued to sink in early trade. Most of the sectors have lost ground this morning, with energy stocks weighing heaviest on the market. Shares in regenerative medicine darling Mesoblast (ASX:MSB) tumbled around 40% this morning after news that the US FDA approval for its lead drug candidate was not going to be the smooth sailing investors had hoped for.
Heavyweights knock ASX lower; Tech soars; Mesoblast hammered 2020/10/02 02:16:53 TheAge
All the latest ASX news from Markets Live team. Reporting on the ASX200 today, Australia's top stocks, the Aussie dollar (AUD), and breaking business news
Mesoblast's (ASX:MSB) good COVID-19 news | Rask Media 2020/09/04 22:15:04 Rask Media
Mesoblast Limited (ASX:MSB) shares dropped 3% on Friday after announcing news relating to COVID-19 patients.
Buy, hold, sell: Telstra, CSL, Mesoblast, Dacian Gold, EML Payments 2020/09/04 01:56:52 The Australian Financial Review
These stocks are the most searched-for on Livewire Markets – but are they a buy?
The Daily Biotech Pulse: Amarin's Vascepa Appeal Hearing, Avid Bioservices' Strong Q1, A Life Sciences Blank Check IPO 2020/09/02 11:25:11 Benzinga
Scaling The Peaks (Biotech Stocks Hitting 52-week Highs Sept. 1) 10X Genomics Inc (NASDAQ: TXG ) Acutus Medical Inc (NASDAQ: AFIB ) Akouos Inc (NASDAQ: AKUS ) Catalent Inc (NYSE: CTLT ) Evogene Ltd (NASDAQ: EVGN ) (announced $10 million equity investment led by ARK Investment Management) I-Mab ADR (NASDAQ: IMAB ) Immunomedics, Inc. (NASDAQ: IMMU ) Intuitive Surgical, Inc. (NASDAQ: ISRG ) Pacific Biosciences of California Inc (NASDAQ: PACB ) PPD Inc (NASDAQ: PPD ) Shockwave Medical Inc (NASDAQ: SWAV ) Tandem Diabetes Care Inc (NASDAQ: TNDM ) TG Therapeutics Inc common stock (NASDAQ: TGTX ) Twist Bioscience Corp (NASDAQ: TWST ) West Pharmaceutical Services Inc. (NYSE: WST ) Down In The Dumps (Biotech Stocks Hitting 52-week Lows Sept. 1) Acasti Pharma Inc (NASDAQ: ACST ) ADiTx Therapeutics Inc (NASDAQ: ADTX ) China SXT Pharmaceuticals Inc (NASDAQ: SXTC ) Entera Bio Ltd (NASDAQ: ENTX ) Freeline Therapeutics Holdings PLC (NASDAQ: FRLN ) Happiness Biotech Group Ltd (NASDAQ: HAPP ) Histogen Inc (NASDAQ: HSTO ) Immatics NV (NASDAQ: IMTX ) NanoVibronix Inc (NASDAQ: NAOV ) Oncternal Therapeutics Inc (NASDAQ: ONCT ) Predictive Oncology Inc (NASDAQ: POAI ) Rockwell Medical Inc (NASDAQ: RMTI ) Sun BioPharma, Inc. (NASDAQ: SNBP ) Stocks In Focus Mesoblast Gets Ethics Approval For Using Stem Cell Therapy In COVID-19 Patients In Australia Mesoblast (NASDAQ: MESO ) said it has received ethics approval to include Australian hospitals in the Phase 3 randomized controlled trial of remestemcel-L in ventilator-dependent COVID-19 patients with acute respiratory distress syndrome.
Mesoblast (ASX:MSB) receives ethics approval to treat Covid-19 patients 2020/09/02 01:41:00 Finance News Network
02 Sep 2020 - Mesoblast (ASX:MSB) today announced that it has received ethics approval to include Australian hospitals in the controlled trial of remestemcel-L Covid-19 patients with acute respiratory distress syndrome (ARDS).